The stock of Lyell Immunopharma Inc (LYEL) has seen a -25.48% decrease in the past week, with a -38.75% drop in the past month, and a -45.66% decrease in the past quarter. The volatility ratio for the week is 10.32%, and the volatility levels for the past 30 days are at 10.36% for LYEL. The simple moving average for the past 20 days is -28.02% for LYEL’s stock, with a -61.02% simple moving average for the past 200 days.
Is It Worth Investing in Lyell Immunopharma Inc (NASDAQ: LYEL) Right Now?
Moreover, the 36-month beta value for LYEL is -0.45. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for LYEL is 144.26M and currently, short sellers hold a 6.55% of that float. On December 16, 2024, LYEL’s average trading volume was 1.35M shares.
LYEL) stock’s latest price update
Lyell Immunopharma Inc (NASDAQ: LYEL)’s stock price has gone decline by -11.37 in comparison to its previous close of 0.76, however, the company has experienced a -25.48% decrease in its stock price over the last five trading days. zacks.com reported 2024-12-13 that Lyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Analysts’ Opinion of LYEL
Many brokerage firms have already submitted their reports for LYEL stocks, with BofA Securities repeating the rating for LYEL by listing it as a “Underperform.” The predicted price for LYEL in the upcoming period, according to BofA Securities is $1 based on the research report published on October 30, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see LYEL reach a price target of $1, previously predicting the price at $6. The rating they have provided for LYEL stocks is “Neutral” according to the report published on June 27th, 2024.
JP Morgan gave a rating of “Neutral” to LYEL, setting the target price at $5 in the report published on August 28th of the previous year.
LYEL Trading at -36.17% from the 50-Day Moving Average
After a stumble in the market that brought LYEL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.30% of loss for the given period.
Volatility was left at 10.36%, however, over the last 30 days, the volatility rate increased by 10.32%, as shares sank -38.75% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -43.38% lower at present.
During the last 5 trading sessions, LYEL fell by -25.48%, which changed the moving average for the period of 200-days by -76.92% in comparison to the 20-day moving average, which settled at $0.9361. In addition, Lyell Immunopharma Inc saw -65.27% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for LYEL
Current profitability levels for the company are sitting at:
- -3488.44 for the present operating margin
- -236.81 for the gross margin
The net margin for Lyell Immunopharma Inc stands at -3237.92. The total capital return value is set at -0.38. Equity return is now at value -33.22, with -28.85 for asset returns.
Currently, EBITDA for the company is -226.76 million with net debt to EBITDA at 0.25. When we switch over and look at the enterprise to sales, we see a ratio of 2349.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.43.
Conclusion
To wrap up, the performance of Lyell Immunopharma Inc (LYEL) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
